25th Annual Meeting of the European Charcot Foundation, November 30 till December 2, 2017, Baveno (IT)
 
Posters presented by Investigators:

Basic Studies
ROSSI Stefania Italy Intrathecal B-cell inflammation may mediate cortical pathology in multiple sclerosis at time of diagnosis by influencing macrophage and haemoglobin activity
Abstract
SELLNER Johann Austria Adaptive immune responses associated with acute varicella-zoster virus reactivation during treatment with fingolimod
Abstract

Clinical
BUTERA Carla Italy Focal spasticity in multiple sclerosis: experience on botulinum toxin type A treatment at San Raffaele Hospital
Abstract
TZANETAKOS Dimitrios Greece The burden of urological and sexual dysfunction in multiple sclerosis : Study of a large Greek cohort
View poster     -     Abstract

Epidemiology
ALTINTAS Ayse Turkey Smoking in MS and correlation with IL17&IL23 levels
Abstract
CASTILLO GARCÍA Omar Isaac Mexico Decrease of relapse rate in Neuromielitis optica patients (AQP4 positive) at the National Institute of Neurology and Neurosurgery (Mexico)
View poster     -     Abstract
RIECKMANN Peter Germany A mapping study to compare the educational offerings for patients in the fields of multiple sclerosis and HIV in Europe and Canada
View poster     -     Abstract     -     View poster presentation

Investigations
MONTALBAN Xavier Spain Interim Analysis From FLOODLIGHT: A prospective pilot study to evaluate the feasibility of conducting remote patient monitoring with the use of digital technology in patients with multiple sclerosis
Abstract

Treatments
ABI-GERGES Najah United States Effect of Ozanimod (RPC1063) on action potential parameters in adult human Purkinje fibers
View poster     -     Abstract
ARNOLD Douglas Canada Ozanimod demonstrates preservation of brain volume at 1 and 2 years in two phase 3 trials of relapsing multiple sclerosis (SUNBEAM and RADIANCE)
View poster     -     Abstract
BERTOLOTTO Antonio Italy Low conversion rate from relapsing-remitting MS to secondary progressive MS in patients treated with Alemtuzumab: 6-Year follow-up of CARE-MS I and II
View poster     -     Abstract     -     View poster presentation
COHEN Jeffrey A. United States Ozanimod vs Interferon β-1a: Clinical and magnetic resonance imaging (MRI) results of RADIANCE Part B – A 2-Year Phase 3 trial in relapsing multiple sclerosis (RMS)
View poster     -     Abstract
COMI Giancarlo Italy Cardiac safety of ozanimod in a QT/QTc trial and a phase 2 trial in relapsing multiple sclerosis (RMS)
View poster     -     Abstract
COMI Giancarlo Italy Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM)
View poster     -     Abstract
COOK Stuart United States Rates of lymphopenia in Years 1–4 in patients with relapsing multiple sclerosis treated annually with Cladribine tablets
View poster     -     Abstract
COOK Stuart United States Infections and grade 3 or 4 lymphopenia in patients taking cladribine tablets 3.5 mg/kg: data from an integrated safety analysis
View poster     -     Abstract
DEFTEREOS Spyros Greece Evaluation of the effect of seasonal weather variations on adherence and effectiveness of subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: final results of the 1-year, observational GEPAT-SMART study
View poster     -     Abstract     -     View poster presentation
GALAZKA Andrew Switzerland An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis
View poster     -     Abstract
GALAZKA Andrew Switzerland Pregnancy outcomes during the clinical development of cladribine in multiple sclerosis: an integrated analysis of safety for all exposed patients
View poster     -     Abstract
GIOVANNONI Gavin United Kingdom Proportions of patients with highly active RMS achieving no evidence of disease activity in response to cladribine tablets in CLARITY
View poster     -     Abstract
GIOVANNONI Gavin United Kingdom Radiological outcomes with cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis in the CLARITY study
View poster     -     Abstract
GIOVANNONI Gavin United Kingdom A pooled analysis of the efficacy of cladribine tablets 3.5 mg/kg in RMS patients with EDSS ≥3.5 or ≤3.0 at baseline in the CLARITY and ONWARD studies
View poster     -     Abstract     -     View poster presentation
LEBRUN-FRENAY Christine France Teriflunomide (Aubagio[R]) international pregnancy registry: Enrollment update
View poster     -     Abstract     -     View poster presentation
MONTALBAN Xavier Spain Efficacy of cladribine tablets 3.5 mg/kg added to interferon-beta in patients with secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS): a post-hoc analysis from ONWARD
Abstract     -     View poster presentation  
SOELBERG-SORENSEN Per Denmark Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with Cladribine tablets 3.5 mg/kg in CLARITY/CLARITY extension
View poster     -     Abstract
STUVE Olaf United States Effects of cladribine tablets on B and T lymphocytes and natural killer cells in patients with early and relapsing MS
View poster     -     Abstract     -     View poster presentation
STUVE Olaf United States Effects of cladribine tablets on CD4+ T cell subsets in the ORACLE-MS study: An analysis of lymphocyte surface markers
View poster     -     Abstract     -    View poster presentation
SU Wendy United States 6 Month results of a phase 2a multicenter study of Ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in relapsing multiple sclerosis
Abstract     -     View poster presentation
TAYLOR MEADOWS Kristen United States Ozanimod (RPC1063) reduces the plasma biomarker neurofilament light chain in preclinical rodent
View poster     -     Abstract
VARGAS SANTANA Sarah Berenise Mexico Number of relapses in patients with autoimmune encephalitis by anti NMDAR antibodies with or without immunomodulatory treatment and with maintenance treatment
View poster     -     Abstract
VERMERSCH Patrick France Efficacy of a third course of Alemtuzumab in patients with active relapsing-remitting multiple sclerosis who experienced disease activity after the initial two courses: Pooled analysis of CARE-MS I and II
View poster     -     Abstract
VERMERSCH Patrick France Benefit-risk assessment of cladribine tablets using Multi-criteria decision analysis (MCDA) for patients with relapsing multiple sclerosis demonstrating high disease activity
View poster     -     Abstract